Plain-English translation of NCT04700826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
DaRe2THINK is testing whether people with atrial fibrillation (irregular heartbeat) who are at lower risk of stroke should start taking (DOACs)—blood-clotting medications like apixaban, dabigatran, edoxaban, or rivaroxaban—to prevent strokes and other blood clots. Right now, these medications are usually only given to people at higher risk. This trial will see if giving the medication to younger, lower-risk patients can prevent serious health events and keep their thinking sharp as they age.
Doctors are not sure whether younger people with irregular heartbeats who have a lower stroke risk should take blood-clotting medication. This trial will help answer that question and show whether the medication is worth the benefits and any possible side effects.
You likely qualify if…
You likely don't qualify if…
You will be randomly placed into one of two groups: either starting the blood-clotting medication or continuing with your usual care. The trial uses your existing medical records to track your health over time, so you won't need extra clinic visits. Researchers will check in with you remotely using online consent and surveys about your memory and thinking. The study will follow you for 5 years, with some health outcomes tracked for up to 10 years.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United Kingdom